Evolus, Inc. (EOLS) États Financiers et Données Historiques

Evolus, Inc. (EOLS) — Prix $7.99 HealthcareDrug Manufacturers - Specialty & Generic — NASDAQ

Derniers résultats publiés:

États financiers détaillés de Evolus, Inc. (EOLS): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.

Résumé de l'Analyse

Evolus, Inc. a enregistré un chiffre d'affaires de $297.2M sur le dernier exercice, avec un CAGR sur 5 ans de 39.4%.

Marges des 12 derniers mois: marge brute 66.2%, marge opérationnelle -7.3%, marge nette -10.8%.

Au prix actuel de $7.99, EOLS affiche des résultats négatifs (PER non significatif) et un ROE de 123.11%. La capitalisation boursière s'établit à $526M.

Compte de Résultat (10 ans)

Année2016201720182019202020212022202320242025
Revenus000$34.9M$56.5M$99.7M$148.6M$202.1M$266.3M$297.2M
Coût des Ventes$326000$218000$9000$8.0M$18.3M$43.5M$58.8M$61.6M$84.0M$104.4M
Marge Brute-$326000-$218000-$9000$26.9M$38.2M$56.1M$89.8M$140.5M$182.3M$192.8M
R&D$12.6M$6.7M$6.5M$4.0M$1.7M$2.1M$6.7M$15.4M$9.2M$9.6M
Frais Généraux$7.0M$4.8M$29.1M$113.6M$98.2M$112.1M$141.8M$164.9M$198.0M$220.8M
Charges Opérationnelles$20.0M$11.7M$35.6M$125.9M$191.3M$100.5M$155.1M$189.8M$216.7M$230.4M
Résultat Opérationnel-$20.0M-$11.7M-$46.1M-$98.9M-$153.1M-$44.4M-$65.3M-$49.2M-$34.4M-$37.6M
EBITDA-$19.6M-$11.5M-$46.1M-$92.1M-$144.8M-$39.1M-$53.9M-$41.8M-$25.0M-$22.5M
Charges d'Intérêt00$863000$8.0M$10.5M$1.4M$9.1M$13.8M$18.7M$19.7M
Résultat Avant Impôts-$20.0M-$11.7M-$46.8M-$105.1M-$162.9M-$46.8M-$74.3M-$61.5M-$49.8M-$51.0M
Impôts$93000-$7.3M$65000-$15.0M$77000$42000$95000$176000$664000$677000
Résultat Net-$20.1M-$4.5M-$46.9M-$90.0M-$163.0M-$46.8M-$74.4M-$61.7M-$50.4M-$51.6M
BPA$-1.08$-0.19$-1.92$-3.19$-4.83$-0.94$-1.33$-1.08$-0.81$-0.80
BPA Dilué$-1.08$-0.19$-1.92$-3.19$-4.83$-0.94$-1.33$-1.08$-0.81$-0.80
Actions en Circulation (Diluées)$18.6M$23.6M$24.4M$28.2M$33.7M$49.8M$56.1M$56.9M$62.0M$64.5M

Compte de Résultat (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Revenus$69.0M$90.3M$73.1M$84.1M
Marge Brute$45.8M$59.3M$47.4M$57.2M
Résultat Opérationnel-$11.5M-$291000-$6.9M-$4.5M
EBITDA-$9.5M$7.1M-$3.8M-$4.0M
Résultat Net-$15.7M$130000-$10.7M-$8.1M
BPA$-0.24$0.00$-0.16$-0.12
BPA Dilué$-0.24$0.00$-0.16$-0.12

Bilan (10 ans)

Année2016201720182019202020212022202320242025
Trésorerie00$93.2M$109.9M$102.6M$146.3M$53.9M$62.8M$87.0M$53.8M
Placements à Court Terme000$19.9M$5.0M00000
Créances0$72.6M0$10.7M$9.7M$14.7M$22.4M$30.5M$47.7M$54.7M
Stocks000$6.4M$3.4M$1.8M$18.9M$11.0M$12.2M$27.0M
Actifs Courants$211000$72.8M$94.3M$152.2M$127.6M$178.8M$100.8M$112.4M$151.3M$142.9M
Immobilisations Corporelles000$5.0M$4.7M$4.1M$4.6M$7.8M$10.4M$12.5M
Goodwill$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M
Actifs Incorporels$56.1M$56.1M$56.1M$59.6M$55.3M$50.6M$48.6M$47.1M$48.8M$48.0M
Actifs Totaux$77.5M$152.2M$171.8M$240.4M$209.1M$257.5M$178.0M$189.0M$232.6M$225.9M
Dettes Fournisseurs$2.9M$445000$1.6M$5.8M$9.6M$6.1M$8.9M$4.3M$9.2M$23.4M
Dette à Court Terme$59.8M$211.3M00$93.5M00000
Passifs Courants$63.3M$212.7M$5.3M$24.4M$180.2M$57.7M$46.5M$48.3M$63.0M$75.3M
Dette à Long Terme00$16.9M$91.5M$40.5M$71.2M$71.9M$120.4M$121.5M$146.1M
Passifs Totaux$84.6M$227.8M$87.5M$161.0M$282.0M$175.6M$159.5M$209.7M$227.0M$249.0M
Réserves-$66.8M-$75.5M-$123.0M-$213.1M-$376.1M-$422.9M-$497.3M-$559.0M-$609.4M-$661.0M
Capitaux Propres-$7.1M-$75.5M-$123.0M$79.5M-$73.0M$81.9M$18.5M-$20.7M$5.5M-$23.1M
Dette Totale$59.8M$211.3M$16.9M$96.5M$138.3M$74.7M$74.4M$126.5M$130.0M$155.0M
Dette Nette$59.8M$211.3M-$76.3M-$33.3M$30.8M-$71.5M$20.5M$63.7M$43.0M$101.2M
Fonds de Roulement-$63.1M-$139.9M$89.1M$127.8M-$52.6M$121.1M$54.3M$64.1M$88.4M$67.6M

Bilan (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Trésorerie$43.5M$53.8M$49.8M$45.2M
Actifs Totaux$219.0M$225.9M$220.6M$248.0M
Passifs Totaux$247.8M$249.0M$249.4M$278.9M
Capitaux Propres-$28.8M-$23.1M-$28.8M-$30.9M
Dette Totale$154.9M$155.0M$164.9M$164.8M

Tableau de Flux (10 ans)

Année2016201720182019202020212022202320242025
Résultat Net-$20.1M-$4.5M-$46.9M-$90.0M-$163.0M-$46.8M-$74.4M-$61.7M-$50.4M-$51.6M
Amortissements$326000$218000$9000$5.0M$7.7M$6.3M$4.5M$5.9M$6.0M$8.7M
Stock-based Compensation$957000$586000$7.0M$9.5M$10.6M$9.6M$10.8M$16.5M$22.3M$20.7M
Variation du BFR$5.4M-$2.1M$2.8M-$20.8M$35.6M-$11.5M-$34.3M-$5.9M-$6.6M-$22.5M
Cash Flow Opérationnel-$13.3M-$13.0M-$25.7M-$93.4M-$57.9M-$33.4M-$84.9M-$34.0M-$18.0M-$42.3M
CapEx00-$9000-$4.6M-$3.1M-$970000-$2.9M-$1.6M-$1.5M-$8.5M
Acquisitions000$4.2M$2.3M00000
Rachat d'Actions0000000000
Dividendes Payés0000000000
Free Cash Flow-$13.3M-$13.0M-$25.7M-$98.0M-$61.0M-$34.4M-$87.9M-$35.6M-$19.5M-$50.7M

Tableau de Flux (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Cash Flow Opérationnel-$14.7M$12.8M-$10.0M-$3.6M
CapEx-$2.2M-$2.2M-$1.7M$1.2M
Free Cash Flow-$16.8M$10.7M-$11.6M-$2.4M
Dividendes Payés0000
Stock-based Compensation$5.1M$5.1M$5.1M$5.6M

Croissance et Marges (10 ans)

Année2016201720182019202020212022202320242025
Croissance Revenus (annuelle)+61.9%+76.3%+49.1%+36.0%+31.8%+11.6%
Croissance Résultat Net (annuelle)+77.7%-946.1%-92.1%-81.1%+71.3%-59.0%+17.1%+18.3%-2.4%
Croissance BPA (annuelle)+82.4%-910.5%-66.1%-51.4%+80.5%-41.5%+18.8%+25.0%+1.2%
Variation Actions (annuelle)+26.9%+3.4%+15.7%+19.5%+47.5%+12.6%+1.5%+9.0%+4.0%
Croissance FCF (annuelle)+1.7%-97.0%-281.5%+37.7%+43.7%-155.7%+59.4%+45.4%-160.5%
Marge Brute77.1%67.6%56.3%60.4%69.5%68.5%64.9%
Marge Opérationnelle-283.3%-270.7%-44.6%-44.0%-24.4%-12.9%-12.7%
Marge EBITDA-263.7%-256.0%-39.2%-36.2%-20.7%-9.4%-7.6%
Marge Nette-257.8%-288.3%-47.0%-50.1%-30.5%-18.9%-17.4%
Marge FCF-280.5%-107.9%-34.5%-59.1%-17.6%-7.3%-17.1%
Taux d'Imposition Effectif-0.5%61.8%-0.1%14.3%-0.0%-0.1%-0.1%-0.3%-1.3%-1.3%

Données par Action (10 ans)

Année2016201720182019202020212022202320242025
FCF par Action$-0.71$-0.55$-1.05$-3.47$-1.81$-0.69$-1.57$-0.63$-0.31$-0.79
Dividende par Action$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Actions en Circulation (Basiques)$18.6M$23.6M$24.4M$28.2M$33.7M$49.8M$56.1M$56.9M$62.0M$64.5M

Quoi regarder en Santé / Pharma

Le pipeline R&D est l'actif invisible. Brevets qui expirent = revenus qui s'évaporent. Regardez innovation et cash flow.

Rentabilité

Rentabilité des capitaux propres123.11%
Rentabilité du capital investi-15.27%
Rentabilité des actifs-13.84%
Marge brute66.25%
Marge opérationnelle-7.33%
Marge nette-10.85%

Santé financière

Dette / Capitaux propres-5.33
Ratio de liquidité1.70
Piotroski F-Score2
Altman Z-Score-1.94

Ratios Clés (10 ans)

Année2016201720182019202020212022202320242025
PER-10.65-60.53-6.20-3.82-0.70-6.93-5.65-9.75-13.63-8.31
P/B-30.09-3.59-2.364.33-1.553.9622.76-28.97123.99-18.55
P/V0.000.000.009.842.003.252.832.972.571.44
Marge Brute0.0%0.0%0.0%77.1%67.6%56.3%60.4%69.5%68.5%64.9%
Marge Opérationnelle0.0%0.0%0.0%-283.3%-270.7%-44.6%-44.0%-24.4%-12.9%-12.7%
Marge Nette0.0%0.0%0.0%-257.8%-288.3%-47.0%-50.1%-30.5%-18.9%-17.4%

Entreprises liées: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI

Explorer le secteur: Healthcare · Drug Manufacturers - Specialty & Generic

Plus de sections de EOLS: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements

Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions